In-house roundup: 5G licensing challenges; second medical use solutions; PTAB tactics against NPEs; dosage regimen inventive step

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

In-house roundup: 5G licensing challenges; second medical use solutions; PTAB tactics against NPEs; dosage regimen inventive step

effbdf

Managing IP rounds up the latest news and analysis from patent-focused businesses on 5G, the PTAB, inventive step and second medical use reform

effbdf

5G set to exacerbate FRAND problems, say top patent holders

With more diverse non-telecoms businesses using 5G tech, licensing discussions for standard essential patents are likely to increase and become more difficult to negotiate, leading patentees to promote better licensing education. Read More... 

Prescription reform needed to avoid second medical use infringement

Generic and innovator in-house lawyers agree that serious reform to the way medications are prescribed is needed to avoid patent infringement on secondary uses, and that they will need to work together to make that change. Read more... 

How tech companies use the PTAB to fight patent trolls

Senior sources from high-tech, gaming and financial services companies explain how they succeed in their inter partes reviews and covered business method actions to invalidate broad patents filed by non-practising entities. Read more... 

Inventive step: pharma innovators say "routine testing is never routine"

After the UK Supreme Court's ruling in Acatvis v Icos, pharma innovators say there is no such thing as routine testing and that it is difficult to discern what might be considered obvious in dosage regimens. Read more... 

Sign up to receive more content like this in Patent Strategy’s weekly newsletter.




more from across site and SHARED ros bottom lb

More from across our site

After almost a quarter of a century, Marshall Gerstein has a new managing partner
Abbott winning another round against Sinocare and Menarini, and 'long arm' clarification on the UK's position within the UPC, were also among major developments
Maria Peyman, head of IP at Birketts, explains why the firm is adopting a ‘seamless approach’ for clients by integrating two of its practice areas
Matthew Swinn, who leads the firm’s IP practice, discusses why Mallesons is well-placed to remain a major IP force
Lawyers at A&O Shearman analyse developments regarding UPC’s long-arm jurisdiction, including its scope and jurisdictional limits
Michelle Lee discusses reaching milestones at the USPTO, AI’s role in legal work, and how to empower women in tech and IP
Executive chair Matt Dixon, who reveals a new associate hire, says the firm wants to offer a realistic pathway to partnership while avoiding the ‘corporate machine’ route
Mayer Brown’s role in cardiovascular technology dispute reflects how firms are pursuing precedent-setting cases to try and guide AI and patent law
Kevin Mack, Via’s new president, emphasises the importance of collaborative licensing structures and shares how AI tools can help create new lines of business
A Tokyo District Court ruling concerning movie spoilers, and a second chance for VLSI against Intel were also among the top talking points
Gift this article